LFA102

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Castration-resistant Prostate CancerCastration-resistant Prostate Cancer, Advanced Breast CancerMetastatic Breast CancerUterine Leiomyoma

Phase 1

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

CompletedNCT01338831

Novartis PharmaceuticalsCastration-resistant Prostate Cancer, Metastatic Breast Cancer, Uterine Leiomyoma

Start: 2011-09-30End: 2014-03-31Updated: 2020-12-17

A Phase I Study of LFA102 in Japanese Patients

CompletedNCT01610050

Novartis PharmaceuticalsCastration-resistant Prostate Cancer, Advanced Breast Cancer

Start: 2012-06-30End: 2014-02-28Updated: 2014-11-11